Promising Tanibirumab Trial Boosts PharmAbcine’s Confidence

PharmAbcine is counting on the success of its lead anticancer antibody tanibirumab following promising early Phase II results, and the South Korean bioventure is planning to raise new funds as it looks to progress this and other pipeline projects.

chart

PharmAbcine Inc. says it is receiving "remarkable" data from a Phase IIa Australian trial with tanibirumab, the South Korean bioventure’s anti-VEGFR2/KDR antibody, in an aggressive form of brain cancer.

"Our Australia trial is proceeding smoothly. Eight months of progression-free survival [PFS] in recurrent GBM [glioblastoma multiforme] patients is a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia